


## Pelubiprofen

## Chemical Properties

CAS No. :	69956-77-0
Formula:	C16H18O3
Molecular Weight:	258.31
Storage:	Keep away from moisture Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	Pelubiprofen is an orally active, non-steroidal anti-inflammatory agent, a selective cyclooxygenase-2 (COX-2) inhibitor, which effectively reduces PGE(2) production by inhibiting COX activity. Pelubiprofen inhibits LPS-induced phosphorylation of IKK- $\beta$ and transforming growth factor- $\beta$ activated kinase-1 (TAK1).
Targets(IC50)	NF- $\kappa$ B,MAPK,NO Synthase,COX,IkB/IKK

## Solubility Information

Solubility	DMSO: 80 mg/mL (309.71 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (12.78 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.8713 mL	19.3566 mL	38.7132 mL
5 mM	0.7743 mL	3.8713 mL	7.7426 mL
10 mM	0.3871 mL	1.9357 mL	3.8713 mL
50 mM	0.0774 mL	0.3871 mL	0.7743 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Choi IA, Baek HJ, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. *BMC Musculoskelet Disord.* 2014 Nov 18;15:375.

Shin JS, et al. Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- $\kappa$ B inactivation. *J Cell Biochem.* 2011 Dec;112(12):3594-603.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481